

REFERENCES

1. Centers for Disease Control and Prevention. *Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol --- United States, 1999--2002 and 2005--2008. Morbidity and Mortality Weekly Report (MMWR)*. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm6004a5.htm?s_cid=mm6004a5_w. Published February 4, 2011. Accessed March 4, 2019.
2. Chastain DB, Stover KR, Riche DM. Evidence-based review of statin use in patients with HIV on antiretroviral therapy. *J Clin Transl Endocrinol*. 2017;8:6-14.
3. Feinstein MJ, Achenbach CJ, Stone NJ, Lloyd-Jones DM. A systematic review of the usefulness of statin therapy in HIV-infected patients. *Am J Cardiol*. 2015;115(12):1760-1766.
4. Grundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. *Circulation*. 2018;71(6).
5. National Institutes of Health. *What's New in the Guidelines? Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV*. U.S. Department of Health and Human Services. <https://aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-arv/0>. Published October 25, 2018. Accessed March 4, 2019.
6. Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Statin use for the primary prevention of cardiovascular disease in adults. *JAMA*. 2016;316(19):1997-2007.
7. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. *Clin Infect Dis*. 2007;45(8):1074-1081.
8. Freiberg MS, Chang CC, Kuller LH, et al. HIV infection and the risk of acute myocardial infarction. *JAMA Intern Med*. 2013;173(8):614-22.
9. World Health Organization. *Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection*. <https://www.who.int/hiv/pub/arv/arv-2016/en/>. Published March 13, 2018. Accessed March 4, 2019.